Skip to main content

Generic Vimpat Availability

Last updated on Jan 11, 2023.

Vimpat is a brand name of lacosamide, approved by the FDA in the following formulation(s):

VIMPAT (lacosamide - solution;intravenous)

  • Manufacturer: UCB INC
    Approval date: October 28, 2008
    Strength(s): 200MG/20ML (10MG/ML) [RLD] [AP]

VIMPAT (lacosamide - solution;oral)

  • Manufacturer: UCB INC
    Approval date: April 20, 2010
    Strength(s): 10MG/ML [RLD] [AA]

VIMPAT (lacosamide - tablet;oral)

  • Manufacturer: UCB INC
    Approval date: October 28, 2008
    Strength(s): 50MG [RLD] [AB], 100MG [RLD] [AB], 150MG [RLD] [AB], 200MG [RLD] [AB]

Has a generic version of Vimpat been approved?

A generic version of Vimpat has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Vimpat and have been approved by the FDA:

lacosamide solution;intravenous

  • Manufacturer: ASPIRO
    Approval date: September 14, 2022
    Strength(s): 200MG/20ML (10MG/ML) [AP]
  • Manufacturer: FRESENIUS KABI USA
    Approval date: May 3, 2022
    Strength(s): 200MG/20ML (10MG/ML) [AP]
  • Manufacturer: GLAND PHARMA LTD
    Approval date: September 19, 2022
    Strength(s): 200MG/20ML (10MG/ML) [AP]
  • Manufacturer: INDOCO
    Approval date: April 7, 2022
    Strength(s): 200MG/20ML (10MG/ML) [AP]
  • Manufacturer: ZYDUS PHARMS
    Approval date: June 29, 2022
    Strength(s): 200MG/20ML (10MG/ML) [AP]

lacosamide solution;oral

  • Manufacturer: ALKEM LABS LTD
    Approval date: May 19, 2022
    Strength(s): 10MG/ML [AA]
  • Manufacturer: APOTEX
    Approval date: September 26, 2022
    Strength(s): 10MG/ML [AA]
  • Manufacturer: HETERO LABS LTD III
    Approval date: May 31, 2022
    Strength(s): 10MG/ML [AA]
  • Manufacturer: NOVITIUM PHARMA
    Approval date: August 26, 2022
    Strength(s): 10MG/ML [AA]

lacosamide tablet;oral

  • Manufacturer: ACCORD HLTHCARE
    Approval date: July 12, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: ACTAVIS LABS FL INC
    Approval date: January 5, 2023
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: ALEMBIC PHARMS
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: ALKEM LABS LTD
    Approval date: March 31, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: AMNEAL PHARMS
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: APOTEX
    Approval date: September 23, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: AUROBINDO PHARMA LTD
    Approval date: January 5, 2023
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: GLENMARK PHARMS LTD
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: HETERO LABS LTD V
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: INDOCO
    Approval date: March 17, 2022
    Strength(s): 150MG [AB], 200MG [AB], 50MG [AB], 100MG [AB]
  • Manufacturer: MSN LABS PVT LTD
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: SCIEGEN PHARMS INC
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]
  • Manufacturer: SUN PHARM
    Approval date: March 17, 2022
    Strength(s): 50MG [AB], 100MG [AB], 150MG [AB], 200MG [AB]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Vimpat. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

  • Anticonvulsant enantiomeric amino acid derivatives
    Patent RE38551
    Issued: July 6, 2004
    Inventor(s): Harold; Kohn
    Assignee(s): Research Corporation Technologies, Inc.

    The present invention is directed to a compound in the R configuration about the asymmetric carbon in the following formula: pharmaceutical compositions containing same and the use thereof in treating CNS disorders in animals.

    Patent expiration dates:

    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF USE OF TREATING, AS AN INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY IN PARTIAL ONSET SEIZURE PATIENTS WITH EPILEPSY AGED 17 YEARS OR OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF USE AS ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF USE FOR TREATMENT OF PARTIAL-ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING, AS MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL-ONSET SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS AND OLDER WHEN ORAL ADMINISTRATION IS TEMPORARILY NOT FEASIBLE
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING PARTIAL ONSET SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product
    • March 17, 2022
      ✓ 
      Patent use: METHOD OF TREATING, AS INITIAL LOADING DOSE FOR MONOTHERAPY OR ADJUNCTIVE THERAPY, PARTIAL ONSET-SEIZURES IN A PATIENT WITH EPILEPSY AGED 17 YEARS OR OLDER
      ✓ 
      Drug substance
      ✓ 
      Drug product

Related exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

  • Exclusivity expiration dates:

    • November 16, 2023 - NEW PATIENT POPULATION
    • November 16, 2023 - ADDITION OF A NEW INDICATION FOR ADJUNCTIVE THERAPY IN THE TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES IN PATIENTS 4 YEARS OF AGE AND OLDER
    • October 14, 2024 - NEW PATIENT POPULATION

Glossary

Term Definition
Drug Patent A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation.
Drug Exclusivity Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant.
RLD A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart.
AA Products in conventional dosage forms not presenting bioequivalence problems. Products coded as AA contain active ingredients and dosage forms that are not regarded as presenting either actual or potential bioequivalence problems or drug quality or standards issues. However, all oral dosage forms must, nonetheless, meet an appropriate in vitro bioequivalence standard that is acceptable to the Agency in order to be approved.
AB Products meeting necessary bioequivalence requirements. Multisource drug products listed under the same heading (e.g. identical active ingredients, dosage form, and routes of administration) and having the same strength (see Therapeutic Equivalence-Related Terms, Pharmaceutical Equivalents) generally will be coded AB if a study is submitted demonstrating bioequivalence. In certain instances, a number is added to the end of the AB code to make a three character code (e.g. AB1, AB2, AB7). Three-character codes are assigned only in situations when more than one reference listed drug of the same strength has been designated under the same heading. Two or more reference listed drugs are generally selected only when there are at least two potential reference drug products which are not bioequivalent to each other. If a study is submitted that demonstrates bioequivalence to a specific listed drug product, the generic product will be given the same three-character code as the reference listed drug it was compared against.
AP Injectable aqueous solutions and, in certain instances, intravenous non-aqueous solutions. It should be noted that even though injectable (parenteral) products under a specific listing may be evaluated as therapeutically equivalent, there may be important differences among the products in the general category, Injectable; Injection. For example, some injectable products that are rated therapeutically equivalent are labeled for different routes of administration. In addition, some products evaluated as therapeutically equivalent may have different preservatives or no preservatives at all. Injectable products available as dry powders for reconstitution, concentrated sterile solutions for dilution, or sterile solutions ready for injection are pharmaceutical alternative drug products. They are not rated as therapeutically equivalent (AP) to each other even if these pharmaceutical alternative drug products are designed to produce the same concentration prior to injection and are similarly labeled. Consistent with accepted professional practice, it is the responsibility of the prescriber, dispenser, or individual administering the product to be familiar with a product's labeling to assure that it is given only by the route(s) of administration stated in the labeling.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.